Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to IMDELLTRA® (tarlatamab-dlle) for the treatment of adult patients with extensive stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback